3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
6
Carcinoma, Non-Small-Cell Lung
2
Urinary Bladder Neoplasms
1
Testicular Neoplasms
1
Surgery
1
Stress, Psychological
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Seminoma
1
Sarcoma
1
Recurrence
1
Postoperative Complications
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Pancreatic Ductal Adenocarcinoma
1
Ovarian Neoplasms
1
Neoplasms
1
Neoplasm, Residual
1
Neoadjuvant Therapy in Elderly HER2-Positive Breast Cancer
1
Multiple Myeloma
1
Medulloblastoma
1
Lung Neoplasms
1
Liposarcoma
1
Leiomyosarcoma
1
Intermittent Fasting
1
Head and Neck Neoplasms
1
HER2-positive Breast Cancer
1
Esophageal Squamous Cell Carcinoma
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Intraductal, Noninfiltrating
1
Carcinoma, Hepatocellular
1
Interventions
Specimen Handling
52
Carboplatin
49
pembrolizumab
45
Magnetic Resonance Spectroscopy
44
Pemetrexed
39
Cisplatin
34
Paclitaxel
24
durvalumab
23
osimertinib
20
Nivolumab
19
Gemcitabine
19
Radiosurgery
17
Docetaxel
17
atezolizumab
15
Taxes
12
Radiotherapy
12
Immunoglobulin G
12
Disulfides
12
Biopsy
12
130-nm albumin-bound paclitaxel
12
Etoposide
11
Educational Status
11
Radiation
10
Drug Therapy
10
Blood Specimen Collection
10
Platinum
9
Early Intervention, Educational
9
Cetuximab
9
Methods
8
Bevacizumab
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lung Neoplasms
×
Neoadjuvant Therapy
×
90 days
×
Clear all
NCT06788912
2026-06-01
MK-3475-01E
Merck Sharp & Dohme LLC
Phase 2
Recruiting
60 enrolled